Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
11/22/17
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
01/20/11S-1/AAmended Registration statement for face-amount certificate companiesRegistration Statements Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
01/13/11S-1/AAmended Registration statement for face-amount certificate companiesRegistration Statements Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
01/03/11S-1/AAmended Registration statement for face-amount certificate companiesRegistration Statements Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
12/03/10S-1/AAmended Registration statement for face-amount certificate companiesRegistration Statements Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/01/10S-1Registration statement for face-amount certificate companiesRegistration Statements Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
01/08/18WellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize Outcomes Across Surgical Procedures
Agreement will focus on designing and deploying best practice enhanced recovery protocols across therapeutic areas in 11 Georgia-based hospitals PARSIPPANY, N.J. and ATLANTA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- WellStar Health System, the largest health system in Georgia, and Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced a joint commitment to address opioid use and dependence following surgery. Through a comprehensive opioid minimization strategy, the organizations will work togeth... 
Printer Friendly Version
01/04/18Pacira Pharmaceuticals Reports Preliminary 2017 Revenues of $286.6 Million
-- EXPAREL sales of $282.9 million driven by Phase 4 data, education and strategic partnerships -- PARSIPPANY, N.J., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported preliminary unaudited total revenues and EXPAREL® (bupivacaine liposome injectable suspension) net product sales for the fourth quarter and full-year 2017. “2017 was an exciting year marked by solid revenue growth and multiple major milestones that support our mission of improving pat... 
Printer Friendly Version
01/03/18Pacira Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, Inc. is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference at 2:00 PM PT (5:00 PM ET) on Tuesday, January 9, 2018 in San Francisco, CA. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at inve... 
Printer Friendly Version
12/14/17Illinois Surgical Quality Improvement Collaborative and Pacira Pharmaceuticals, Inc. Announce Collaboration to Minimize Opioid Exposure for Postsurgical Patients
Collaboration will develop and distribute evidence-based strategies, education and resources to reduce the overprescribing and optimize the use of opioids across 56 Illinois hospitals PARSIPPANY, N.J. and EVANSTON, Ill., Dec. 14, 2017 (GLOBE NEWSWIRE) -- The Illinois Surgical Quality Improvement Collaborative (ISQIC), a nationally recognized partnership of 56 Illinois hospitals, and Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), today announced an initiative to jointly develop programs and resou... 
Printer Friendly Version
12/08/17Pacira Pharmaceuticals to Present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference
PARSIPPANY, N.J., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference at 11:30 AM ET on Thursday, December 14, 2017 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archiv... 
Printer Friendly Version
12/07/17Pacira Announces Promotions of Scott Braunstein, MD, to Chief Operating Officer and Richard Scranton, MD, to Chief Scientific Officer
Expanded roles reflect key accomplishments and demonstrated leadership PARSIPPANY, N.J., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Scott Braunstein, MD, has been named Chief Operating Officer and Richard Scranton, MD, has been named Chief Scientific Officer. In this new role, Dr. Braunstein will oversee the company’s commercial and medical affairs functions while continuing to manage strategy and corporate development at Pacira.  As Chie... 
Printer Friendly Version
11/29/17Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc. on Innovative Collaboration to Educate Physicians and Patients about Responsible Opioid Use
BOCA RATON, Fla., Nov. 29, 2017 /PRNewswire/ -- Cancer Treatment Centers of America® (CTCA), a national network of five hospitals, and Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on opioid alternatives, today announced a new collaboration dedicated to reducing the risk of opioid dependence among cancer patients. The goal of the Opioid Risk Reduction Initiative—an educational effort focused on responsible use and increased awareness of opioid alternatives—is to improv... 
Printer Friendly Version
11/14/17Pacira Announces FDA Advisory Committee Meeting to Review sNDA for EXPAREL® as a Nerve Block for Regional Analgesia
PARSIPPANY, N.J., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that its supplemental New Drug Application (sNDA) for EXPAREL® (bupivacaine liposome injectable suspension) as a nerve block for regional analgesia will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC).  The meeting is tentatively scheduled for February 14-15, 2... 
Printer Friendly Version
11/09/17Pacira Pharmaceuticals to Present at Two November Healthcare Conferences
PARSIPPANY, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the following two healthcare conferences: Jefferies 2017 Healthcare Conference in London, on Thursday, November 16, 2017 at 10:00 AM GMT (5:00 AM ET) Piper Jaffray 29th Annual Healthcare Conference in New York City, on Wednesday, November 29, 2017 at 10:00 AM ET A live audio webcast of the Pacira presentation... 
Printer Friendly Version
11/08/17Pacira Pharmaceuticals, Inc. Reports Third Quarter 2017 Financial Results
EXPAREL(R) net product sales of $66.8 million up 3% over prior year third quarter; Full-year EXPAREL net product sales guidance revised to $280 to $285 million; Conference Call Today at 8:30 a.m. ET PARSIPPANY, NJ -- (Marketwired) -- 11/08/17 -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the third quarter ended September 30, 2017. "We continue to make important progress during 2017 as we advance our strategy to expand the ro... 
Printer Friendly Version
>> Access Older Press Releases